Out-of-pocket healthcare expenditures and caps in Patients with chronic conditions

American Journal of Pharmacy Benefits

Volumn 3, Issue 2, 2011, Pages 98-105

  Campbell, Rebecca S ^a   Patel, Vaishali ^b   Gleeson, Michelle ^a   Calimlim, Brian M ^a   Zagari, Martin J ^b   Curkendall, Suellen M ^a  

^a CERNER CORPORATION   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RHEUMATOID ARTHRITIS;

EID: 84859756798     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kaiser Family Foundation. Prescription Drug Trends. May 2007 Update. Fact sheet 3057-06. http://www.kff.org/rxdrugs/3057.cfm. Accessed March 11, 2008.
2. Catlin A, Cowan C, Hartman M, Heffler S; National Health Expenditure Accounts Team. National health spending in 2006: a year of change for prescription drugs [published correction appears in Health Aff (Millwood). 2008;27(2):593]. Health Aff (Millwood). 2008;27(1):14-29.
3. Agovino T. Spending on expensive specialty drugs up 17.5%. Detroit Free Press. 2006 Jun 7. Description here: http://www.medicalnewstoday.com/articles/ 44715.php. Accessed March 3, 2011.
4. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25(5):1319-1331.
5. Dor A, Encinosa W. How Does Cost-Sharing Affect Drug Purchases? Insurance Regimes in the Private Market for Prescription Drugs. September 2004. National Bureau of Economic Research. NBER Working Paper No.10738. http://www.nber. org/papers/w10738. Accessed February 22, 2007.
6. Kaiser Family Foundation and Health Research Educational Trust. Employer Health Benefits 2007 Annual Survey. September 2007 update. Report 7672. http://www.kff.org/insurance/7672/index.cfm. Accessed March 11, 2008.
7. Malkin JD, Goldman DP, Joyce GF. The changing face of pharmacy benefit design. Health Aff (Millwood). 2004;23(1):194-199.
8. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39(12):1293-1304.
9. Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther. 2003;25(12): 3147-3161.
10. Motheral BR, Henderson R. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation. Am J Manag Care. 1999; 5(11):1383-1394.
11. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-2232.
12. Brixner DI, Joish VN, Odera GM, Avey SG, Hanson DM, Cannon HE. Effects of benefit design change across 5 disease states. Am J Manag Care. 2007.
13. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350.
14. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007; 298(1):61-69.
15. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care. 2005;11(10):621-628.
16. Piette JD. Rx for Affordability: Helping Patients Cope With Medication Costs. California HealthCare Foundation Report. Oakland, CA: California HealthCare Foundation; November 1, 2007.
17. Klepser DG, Huether JR, Handke LJ, Williams CE. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance. J Manag Care Pharm. 2007;13(9):765-777.
18. Nau DP, Chi C, Mallya U, Kirking DM. Member satisfaction related to self-reported cost share and difficulty in obtaining prescription drugs in a university pharmacy benefit plan. J Manag Care Pharm. 2007;13(2):135-141.
19. Kunze AM, Gunderson BW, Gleason PP, Heaton AH, Johnson SV. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs-pharmacy and medical benefit spending from 2004 through 2007. J Manag Care Pharm. 2007;13(9):799-806.
20. Slothuus U, Brooks RG. Willingness to pay in arthritis: a Danish contribution. Rheumatology (Oxford). 2000;39(7):791-799.
21. Aristides M, Weston AR, FitzGerald P, Le Reun C, Maniadakis N. Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experiment. Value Health. 2004; 7(4):442-454.
22. Barron AC, Lee TL, Taylor J, et al. Feasibility and construct validity of the parent willingness-to-pay technique for children with juvenile idiopathic arthritis. Arthritis Rheum. 2004;51(6):899-908.
23. Fautrel B, Clarke AE, Guillemin F, et al. Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective. J Rheumatol. 2005;32(3):443-453.
24. Sadri H, MacKeigan LD, Leiter LA, Einarson TR. Willingness to pay for inhaled insulin: a contingent valuation approach. Pharmacoeconomics. 2005;23(12): 1215-1227.
25. Johnson FR, Manjunath R, Mansfield CA, Clayton LJ, Hoerger TJ, Zhang P. High-risk individuals' willingness to pay for diabetes risk-reduction programs. Diabetes Care. 2006;29(6):1351-1356.
26. de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HAP, Koes BW, Steyerberg EW. Patients' preference for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int. 2008;19(7):1029-1037.
27. U.S. Government Accountability Office (GAO). Washington, DC. Employer-Sponsored Health and Retirement Benefits: Efforts to Control Employer Costs and the Implications for Workers. GAO-07-355. March 30, 2007. http://www.gao.gov/ products/GAO-07-355. Accessed March 11, 2008.
28. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care. 2006;12(9): 509-517.
29. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4): 421-429.
30. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum. 2008;59(10):1519-1526.
31. Wharam JF, Galbraith AA, Kleinman KP, Soumerai SB, Ross-Degnan D, Landon BE. Cancer screening before and after switching to a high-deductible health plan. Ann Intern Med. 2008;148(9):647-655.
32. Trivedi AN, Rakowski W, Ayanian JZ. Effect of cost sharing on screening mammography in Medicare health plans. N Engl J Med. 2008;358(4):375-383.
33. Bloom D, Canning D, Sevilla J. The Effect of Health on Economic Growth: Theory and Evidence. November 2001. National Bureau of Economic Research. NBER Working Paper No. 8587. http://www.nber.org/papers/w8587. Accessed September 2008.
34. Cutler DM, McClellan M. Is technological change in medicine worth it? Health Aff (Millwood). 2001;20(5):11-29.
35. Lichtenberg FR. The Expanding Pharmaceutical Arsenal in the War on Cancer. February 2004. National Bureau of Economic Research. NBER Working Paper No. 10328. http://www.nber.org/papers/w10328. Accessed September 2008.
36. Philipson TJ, Jena AB. Who benefits from new medical technologies? Estimates of consumer and producer surpluses for HIV/AIDS drugs. The Berkeley Electronic Press. Forum for Health Economics & Policy. 2006;9(2). http://www.bepress.com/ fhep/biomedical_research/3/. Accessed February 18, 2011.